BlackRock’s Biolase, Inc. BIOL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,007
| Closed | -$191 | – | 5382 |
|
|
2024
Q1 | $191 | Sell |
1,007
-24,011
| -96% | -$11.7K | ﹤0.01% | 5244 |
|
|
2023
Q4 | $28.1K | Hold |
25,018
| – | – | ﹤0.01% | 5042 |
|
|
2023
Q3 | $46.5K | Buy |
25,018
+23,834
| +2,013% | +$126K | ﹤0.01% | 5019 |
|
|
2023
Q2 | $8.37K | Hold |
1,184
| – | – | ﹤0.01% | 5270 |
|
|
2023
Q1 | $33.3K | Sell |
1,184
-60
| -5% | -$2.92K | ﹤0.01% | 5181 |
|
|
2022
Q4 | $80.8K | Sell |
1,244
-1
| -0.1% | -$144 | ﹤0.01% | 5105 |
|
|
2022
Q3 | $302K | Sell |
1,245
-3
| -0.2% | -$1.2K | ﹤0.01% | 4870 |
|
|
2022
Q2 | $572K | Buy |
1,248
+38
| +3% | +$20.9K | ﹤0.01% | 4731 |
|
|
2022
Q1 | $1.07M | Hold |
1,210
| – | – | ﹤0.01% | 4643 |
|
|
2021
Q4 | $1.18M | Buy |
1,210
+5
| +0.4% | +$6.31K | ﹤0.01% | 4611 |
|
|
2021
Q3 | $1.93M | Buy |
1,205
+1
| +0.1% | +$1.63K | ﹤0.01% | 4341 |
|
|
2021
Q2 | $2.1M | Sell |
1,204
-229
| -16% | -$425K | ﹤0.01% | 4248 |
|
|
2021
Q1 | $3.02M | Buy |
1,433
+1,325
| +1,227% | +$3.26M | ﹤0.01% | 4155 |
|
|
2020
Q4 | $113K | Hold |
108
| – | – | ﹤0.01% | 4562 |
|
|
2020
Q3 | $74K | Hold |
108
| – | – | ﹤0.01% | 4556 |
|
|
2020
Q2 | $125K | Sell |
108
-15
| -12% | -$17.1K | ﹤0.01% | 4457 |
|
|
2020
Q1 | $116K | Buy |
123
+4
| +3% | +$6.21K | ﹤0.01% | 4327 |
|
|
2019
Q4 | $164K | Hold |
119
| – | – | ﹤0.01% | 4354 |
|
|
2019
Q3 | $279K | Sell |
119
-1
| -0.8% | -$3.29K | ﹤0.01% | 4272 |
|
|
2019
Q2 | $440K | Buy |
120
+4
| +3% | +$19.2K | ﹤0.01% | 4219 |
|
|
2019
Q1 | $688K | Hold |
116
| – | – | ﹤0.01% | 4028 |
|
|
2018
Q4 | $287K | Hold |
116
| – | – | ﹤0.01% | 4162 |
|
|
2018
Q3 | $599K | Buy |
116
+1
| +0.9% | +$4K | ﹤0.01% | 4107 |
|
|
2018
Q2 | $348K | Buy |
115
+1
| +0.9% | +$3.77K | ﹤0.01% | 4186 |
|
|
2018
Q1 | $578K | Sell |
114
-1
| -0.9% | -$5.62K | ﹤0.01% | 4024 |
|
|
2017
Q4 | $612K | Buy |
115
+1
| +0.9% | +$7.03K | ﹤0.01% | 4020 |
|
|
2017
Q3 | $863K | Sell |
114
-1
| -0.9% | -$8.62K | ﹤0.01% | 3951 |
|
|
2017
Q2 | $1.39M | Sell |
115
-5
| -4% | -$74.2K | ﹤0.01% | 3770 |
|
|
2017
Q1 | $2.02M | Buy |
+120
| New | +$2.18M | ﹤0.01% | 3651 |
|
Other funds holding BIOL
BlackRock's BIOL Position: Q2 2024 in Review
BlackRock sold out of Biolase, Inc. (BIOL) in Q2 2024, closing a stake of 1,007 shares — an estimated $191 sold.
BlackRock first reported a position in BIOL in Q1 2017 and held it in 29 quarters. The position peaked at $3.02M in Q1 2021. 2 funds tracked by Wall St. Rank hold BIOL as of Q2 2024.
- BlackRock reported no remaining Biolase, Inc. position as of Q2 2024 after selling out during the quarter.
- BlackRock sold 1,007 Biolase, Inc. shares in Q2 2024, an estimated $191.
- BlackRock first reported a position in Biolase, Inc. in Q1 2017 and held it in 29 quarters.
- BlackRock's Biolase, Inc. position peaked at $3.02M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2024.
Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.